Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NI-0401 in newly diagnosed type 1 diabetes mellitus
2009-012988-34Phase 2Terminated
- Sponsor
- Lightchain Bioscience
- Start
- Aug 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing NI-0401 with Placebo (2 arms). Primary endpoint: Change in stimulated C-peptide AUC at 6 months. Started Aug 2009; status: terminated.
02
Drugs
foralumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2009-012988-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012988-34.